These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 7374415)

  • 81. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
    Circulation; 1984 May; 69(5):1067A-1090A. PubMed ID: 6368042
    [No Abstract]   [Full Text] [Related]  

  • 82. Treatment of essential hypercholesterolemia with clofibrate and nicotinic acid.
    Nordoy A; Gjone E
    Acta Med Scand; 1970 Dec; 188(6):487-90. PubMed ID: 5494813
    [No Abstract]   [Full Text] [Related]  

  • 83. [Endogenous hypertriglyceridemia].
    Oikawa S
    Nihon Naika Gakkai Zasshi; 1992 Nov; 81(11):1767-71. PubMed ID: 1479216
    [No Abstract]   [Full Text] [Related]  

  • 84. [Lipoproteins and hyperlipoproteinemias].
    Weisweiler P; Schwandt P
    Fortschr Med; 1980 Mar; 98(9):313-6. PubMed ID: 7372258
    [No Abstract]   [Full Text] [Related]  

  • 85. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 86. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Lowering lipids rapidly and permanently with etofibrate].
    von Bock und Polach U
    Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
    [No Abstract]   [Full Text] [Related]  

  • 88. [Dietetic and drug therapy of hyperlipidemias and hyperlipoproteinemia].
    Huth K; Blumenthal J; Schmahl FW
    Med Klin; 1973 Aug; 68(34):1089-97. PubMed ID: 4790868
    [No Abstract]   [Full Text] [Related]  

  • 89. [Arteriosclerosis--nicotinic acid therapy. 2. Alterations in serum lipoproteins. Diagnosis, therapy].
    Gustafson A
    Lakartidningen; 1971 Apr; 68(15):1744-5 passim. PubMed ID: 5577244
    [No Abstract]   [Full Text] [Related]  

  • 90. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ; Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2053-8. PubMed ID: 7194059
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W; Holm E
    Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
    [No Abstract]   [Full Text] [Related]  

  • 92. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
    Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
    [No Abstract]   [Full Text] [Related]  

  • 93. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1974; 19(3):407-15. PubMed ID: 4364073
    [No Abstract]   [Full Text] [Related]  

  • 95. [Comparative studies on the reduction of lipids using clofibric acid and clofibrate in hyperlipoproteinemias].
    Schwartzkopff W; Hoffmann H; Kästner W
    Med Welt; 1975 Dec; 26(51):2308-15. PubMed ID: 177837
    [No Abstract]   [Full Text] [Related]  

  • 96. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 97. [Effects of various modes of therapy on the fatty acid spectrum in hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1977 Jul; 32(13):203-5. PubMed ID: 930182
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P; Bittolo-Bon G; Alessandrini P
    Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
    [No Abstract]   [Full Text] [Related]  

  • 99. [Nicotinic acid and derivatives for therapy of hyperlipoproteinemia].
    Ishikawa T
    Nihon Rinsho; 1994 Dec; 52(12):3292-7. PubMed ID: 7853725
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
    Rajecová E; Klimes I; Seböková E; Rychnavská E; Pleváková L; Linke-Cvrkalová A; Langrová H
    Vnitr Lek; 1995 Oct; 41(10):677-81. PubMed ID: 8578698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.